neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
Published 3 years ago • 223 plays • Length 9:34Download video MP4
Download video MP3
Similar videos
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
3:41
characteristics of neurotoxicity associated with ide-cel in pts with rrmm in phase ii karmma
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
7:23
cartitude-2: efficacy and safety of ciltacabtagene autoleucel in patients with progressive mm
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
4:10
cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
1:25
cartitude-1: outcomes of patients with triple-class exposed multiple myeloma treated with cilta-cel
-
48:06
the latest insights on immune therapies in myeloma | 2023 imf patient and family seminar
-
5:34
latest results from the cartitude-2 study testing cilta-cel in multiple myeloma patients